According to a CFDA law amendment brought to congress vote, certification of drugs in China might be simplified in the future: 1. permission for manufacture and GMP certificate will be combined in one certificate, and 2. permission for storage (GSP = good storage practice certificate) and sales will also be combined in another certificate. Thus, if approved by congress, GMP and GSP will in future be combined with manufacturing and sales certificate (information by XIONG Xin)

China Bio news release, November 29, 2017